TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01836575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
Study: NCT01126970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat Placebo
Description: Orlistat Placebo t.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velneperit Placebo
Description: Velneperit Placebo q.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Velneperit Placebo
Description: Velneperit Placebo q.d

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet
Study: NCT01139489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin-guidance
Description: If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
Study: NCT02628470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: cervical high-velocity low-amplitude thrust manipulation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical control exercises
Description: Exercises of flexion, extension and rotation of the cervical spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory mobilization technique
Description: Joint mobilization technique type III according Maitland
Study: NCT03373292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous stenting for internal jugular vein stenosis
Description: After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis
Description: Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time.
Study: NCT00325273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
Study: NCT01443078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT02998983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racotumomab
Study: NCT02027519

Intervention type: OTHER
Intervention: HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation
Description: Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance
Study: NCT01497457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR saline peritoneography
Description: Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
Study: NCT02974283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:
Study: NCT01390649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
Study: NCT02287012

Intervention type: OTHER
Intervention: Time/Motion evaluation of actual apheresis
Description: The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
Study: NCT04523844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide-brimonidine Fixed Combination
Description: In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
Study: NCT03273270

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: transcranial magnetic stimulation

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: transcranial magnetic stimulation
Study: NCT01182142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,250 mg/m2 orally twice a day, days 1-14
Study: NCT01626430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma delta TRF
Description: 50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma delta TRF
Description: 50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
Study: NCT03407625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foley bulb plus Oral Misoprostol
Description: Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Misoprostol
Description: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
Study: NCT00334321

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary vaginal brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00938236

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Inhalation Solution (CIS)
Description: Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
Study: NCT02667990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthopaedic stilettoe
Description: stilettos with orthopaedic in-sole buildt into the shoe
Study: NCT03404232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynesys DTO device (Zimmer Spine, Inc.)
Description: All patients receive posterior hybrid instrumentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynesys DTO device (Zimmer Spine, Inc.)
Description: All patients receive posterior hybrid instrumentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynesys DTO device (Zimmer Spine, Inc.)
Description: All patients receive posterior hybrid instrumentation.
Study: NCT00270335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT03530969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Assessment
Description: Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCLA Geriatrics Attitudes Scale
Description: The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Course Evaluations
Description: The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Consultation and Relational Empathy (CARE) questionnaire
Description: The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Consultation and Relational Empathy (CARE) questionnaire
Description: The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Description: Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Description: Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient activation measure (PAM) scale
Description: The PAM scale contains 22 items that assess patient engagement in their care process.
Study: NCT02605070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle
Description: Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis.
Study: NCT04049864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella oral vaccine
Description: suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
Study: NCT03823456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
Study: NCT00493454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 IV Over 6 to 8 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^111 In Ibritumomab Tiuxetan
Description: 1.6 mg IV Over 10 Minutes x 1 Day
Study: NCT03860207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized 3F8 Bispecific Antibody
Description: Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: In cycle 1, blood is drawn for PK studies.
Study: NCT04734834

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prodovite® VMP35
Description: Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prodovite® VMP35
Description: Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo
Study: NCT04412057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-002
Description: Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once subcutaneously
Study: NCT04017559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
Study: NCT03823456

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Self-acupressure
Description: We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
Study: NCT02488668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Electrical Stimulation
Description: Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
Study: NCT00779402

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study: NCT01953094

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Anal Pap Smear - No High Resolution Anoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Anal Pap Smear - With High Resolution Anoscopy
Study: NCT04233879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DOR/ISL
Description: Placebo tablet matched to DOR/ISL taken by mouth.
Study: NCT02667990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard stiletto
Description: standard stiletto without insole

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comfy trainer
Description: comfy trainer
Study: NCT03389061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir/velpatasvir tablet
Description: Single-dose SOF/VEL as a whole tablet in a fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir crushed
Description: Single-dose crushed SOF/VEL in a fasted state.
Study: NCT02427477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Subjects will wear the contact lenses in both eyes for seven days
Study: NCT02283671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic cells loaded with myelin peptides
Description: Somatic-cell therapy medicines application
Study: NCT03187028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Only
Description: Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
Study: NCT04476745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
Study: NCT01544062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Study: NCT00684034

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood
Description: A sampling of blood will be made

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood
Description: A sampling of bood will be made before the dialysis

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood
Description: A sampling of blood will be made.
Study: NCT02286765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System treatment
Description: Micro-focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System treatment
Description: Micro-focused ultrasound energy delivered below the surface of the skin
Study: NCT00850681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel
Description: PEP005 (ingenol mebutate) Gel, 0.01%